Gvoke VialDx is expected to be available in the third quarter of 2025. The Food and Drug Administration (FDA) has approved Gvoke VialDx ™ (glucagon) for intravenous use as a diagnostic aid ...

After more than 10 years leading Alabama’s state library agency, Nancy Pack was terminated by the board of trustees at the March 20 board meeting. Pack was fired, effective immediately ...

Earlier this week, the FDA approved Xeris’ supplemental new drug application for Gvoke VialDx for use as a ... The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list ...

The core offerings of the company include Gvoke, Keveyis, and Recorlev, with a series of development programs to expand the approved uses of its commercialized products and the introduction of new ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic ...

The core offerings of the company include Gvoke, Keveyis, and Recorlev, with a series of development programs to expand the approved uses of its commercialized products and the introduction of new ...

You can find him on X @gamegriffin. Languages: English The Batman Part 2 is coming, but so far it's shrouded in mystery. What's the story, who's the villain, and when is it coming out? In this ...

and for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. Arbli is designed for patients who ...

Gvoke VialDx™ will be offered in 1-count or 10-count packages of 1 mg per 0.2 mL single-dose vials. It is also indicated as an antihypoglycemic agent for severe hypoglycemia treatment in diabetic ...